• Explore /
  • Poster
  • / Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.

Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.

Abstract Poster

Authors

null

Guillermo Garcia-Manero

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Guillermo Garcia-Manero , Eric S. Winer , Daniel J. DeAngelo , Stefano R. Tarantolo , David Andrew Sallman , James Dugan , Stefanie Groepper , Aristoteles Giagounidis , Katharina S. Gotze , Klaus Metzeler , Chia-Cheng Li , Li Zhou , Elizabeth Martinez , Maureen E Lane , Reinhard W. Von Roemeling , Matthias Bohme , Anne Sophie Kubasch , Amit K. Verma , Uwe Platzbecker

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

04278768

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7016)

DOI

10.1200/JCO.2022.40.16_suppl.7016

Abstract #

7016

Poster Bd #

247

Abstract Disclosures

Similar Posters

First Author: Alison R. Walker

First Author: Joanna S. Yi

First Author: Musa Yilmaz

First Author: Steven G. DuBois